Radiation To Tumors Articles & Analysis
8 news found
BNCT is a targeted radiation cancer therapy in which neutron beams interact with a boron-bearing compound, taken up selectively by tumors, to create DNA-damaging alpha particles within the tumor cells, sparing neighboring, healthy tissue. BNCT has the potential to deliver highly effective, cell-localized radiation therapy to ...
The study published as part of the special issue of Cancers “Novel Techniques and Technology for Treatment of Brain Tumors”, reports that Spermidine/spermine N1-acetyltransferase 1 (SAT1) inhibition using an ionizable lipid nanoparticle-based siRNA delivery system appears to provide a safe and effective method to sensitizing GB cells to radiation and ...
BNCT is a targeted radiation cancer therapy in which neutron beams destroy only boron compound-bearing tumors without destroying neighboring normal tissue. BNCT has the potential to deliver highly effective and cell-localized radiation therapy to treat tumors with minimal impact on the patient’s quality of life compared to ...
We believe each advisor contributes to our patient centric mission by offering expansive patient care expertise along with deep translational research experience in radiation biology and tumor hypoxia. Up to 90 % of solid tumors are hypoxic, which can contribute to multi-modal treatment resistance, increased risk of metastasis, and decreased ...
ByCervoMed
Given the location and extent of disease, placing a radiopaque filament to help target the adjuvant radiation is extremely helpful, both for allowing better delivery of radiation to the exact tumor bed and limiting radiation spray to other structures such as the heart, lungs and surrounding muscles. In this case, it’s ...
And what if the knowledge gleaned from the preop imaging could be combined with the surgeon’s intraop observations to localize the tumor bed in the most accurate way possible for the radiation oncologist? ...
Edinburgh Molecular Imaging Ltd, a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance new molecular targeted systemic radiotherapy agents, EMT-100 and EMT-101 to be ready for clinic development. Current investors and one new investor supported the round. EMT-100 and EMT-101 have been developed as ...
Using the superior imaging properties of MRI, the applicators can be positioned more precisely allowing for more accurate delivery of radiation to the tumor site while avoiding healthy surrounding organs and tissue. ...